VTYX Sheila Gujrathi buys $301K worth of shares
Dec 27, 2024, 5:33 AM
2.51%
What does VTYX do
Ventyx Biosciences, a San Diego-based clinical-stage biopharmaceutical company, develops small molecule therapeutics for autoimmune diseases with a pipeline including VTX002, VTX958, VTX2735, and VTX3232. The company went public on October 21, 2021, and employs 74 people.
Sheila Gujrathi bought 130,000 shares of VTYX on 23 December at $2.31 per share, worth a total of $301K. They now own 130,000 VTYX shares.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
